Characteristics of HIV-seropositive study patients at the time of T-cell infusions
| Patient . | CD4 cells/μL . | % CD4 . | CD8 cells/μL . | % CD8 . | Viral load, copies/mL plasma . | Years of HIV infection . | Years of HAART . | Total CD4 at time of HAART initiation . | Route of infection . |
|---|---|---|---|---|---|---|---|---|---|
| 7701 | 577 | 19 | 1938 | 64 | < 30 | 8 | 5 | 211 (15%) | MSM |
| 7702 | 898 | 40 | 714 | 32 | < 30 | 20 | 9 | UNK | MSM |
| 7703 | 642 | 25 | 1368 | 54 | < 30 | 21 | 7 | UNK | MSM |
| 7704 | 575 | 34 | 779 | 46 | < 30 | 20 | 9 | 490 | MSM/IVDU |
| 7705 | 539 | 45 | 473 | 40 | < 30 | 6 | 5 | UNK | MSM |
| 7707 | 439 | 22 | 754 | 38 | < 30 | 2 | 1 | 219 | MSM |
| 7709 | 850 | 43 | 682 | 35 | < 30 | 17 | 9 | 320 | MSM |
| Mean | 646 | 33 | 958 | 44 | < 30 | 13.4 | 6.4 |
| Patient . | CD4 cells/μL . | % CD4 . | CD8 cells/μL . | % CD8 . | Viral load, copies/mL plasma . | Years of HIV infection . | Years of HAART . | Total CD4 at time of HAART initiation . | Route of infection . |
|---|---|---|---|---|---|---|---|---|---|
| 7701 | 577 | 19 | 1938 | 64 | < 30 | 8 | 5 | 211 (15%) | MSM |
| 7702 | 898 | 40 | 714 | 32 | < 30 | 20 | 9 | UNK | MSM |
| 7703 | 642 | 25 | 1368 | 54 | < 30 | 21 | 7 | UNK | MSM |
| 7704 | 575 | 34 | 779 | 46 | < 30 | 20 | 9 | 490 | MSM/IVDU |
| 7705 | 539 | 45 | 473 | 40 | < 30 | 6 | 5 | UNK | MSM |
| 7707 | 439 | 22 | 754 | 38 | < 30 | 2 | 1 | 219 | MSM |
| 7709 | 850 | 43 | 682 | 35 | < 30 | 17 | 9 | 320 | MSM |
| Mean | 646 | 33 | 958 | 44 | < 30 | 13.4 | 6.4 |
HAART indicates highly active antiretroviral therapy; UNK, unknown; MSM, men who have sex with men; and IVDU, intravenous drug use.